| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| 500g |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Maltodextrin does not have a specific pharmacological target. It acts primarily as a carbohydrate source in biological systems. In humans, it is rapidly digested and absorbed due to its short-chain structure, providing quick energy. In microbial metabolism, maltodextrins are utilized through uptake and subsequent enzymatic breakdown. As a pharmaceutical excipient, it serves as a binder, filler, or stabilizer in drug formulations without exerting direct pharmacological effects. |
|---|---|
| ln Vitro |
In vitro, maltodextrin with DE 16.5-19.5 is non-toxic to cells at concentrations of 5 mg/mL and can be used in drug delivery systems. It serves as a carbohydrate source in cell culture media, providing energy for cell growth and metabolism. It is also used as a stabilizer in protein formulations, protecting proteins from denaturation or aggregation. Its rapid digestibility and controlled osmolarity make it valuable for studying metabolic pathways and carbohydrate absorption.
|
| ln Vivo |
In vivo, maltodextrin is rapidly broken down to glucose following ingestion. The sodium-dependent glucose transporter SGLT1 and the facilitative glucose transporter GLUT2 are predominantly responsible for the transport of glucose into circulation. As a carbohydrate source, it provides energy and can affect glycemic responses. In animal studies, maltodextrin is used as a control carbohydrate or as a component of dietary formulations. It is also used as a prebiotic fiber to stimulate the growth and activity of gut microbiota.
|
| Enzyme Assay |
In vitro enzyme assays for maltodextrin typically involve measuring its hydrolysis by digestive enzymes such as α-amylase and glucoamylase. The compound is incubated with the enzyme of interest at appropriate pH and temperature, and the release of reducing sugars (e.g., glucose, maltose) is quantified using colorimetric methods such as the dinitrosalicylic acid (DNS) assay. The rate of hydrolysis is used to assess enzyme activity and substrate specificity. Alternatively, maltodextrin can be used as a substrate for studying starch-degrading enzymes.
|
| Cell Assay |
In vitro cell-based assays for maltodextrin involve culturing cells in media containing maltodextrin as the carbohydrate source. Cells are seeded in multi-well plates and cultured in media supplemented with various concentrations of maltodextrin (e.g., 0.1-10 mg/mL). Cell viability, proliferation, and metabolic activity are assessed using standard assays such as MTT, CellTiter-Glo, or glucose consumption measurements. The effects of maltodextrin on cellular metabolism and gene expression can also be evaluated. Cytotoxicity is typically assessed at concentrations up to 5 mg/mL.
|
| Animal Protocol |
In vivo animal studies for maltodextrin typically involve oral administration in rodents to assess its effects on glycemic response, energy metabolism, or gut microbiota. Animals are fasted overnight and then administered maltodextrin (typically 1-3 g/kg body weight) via oral gavage. Blood samples are collected at multiple time points for measurement of glucose, insulin, and other metabolic parameters. For microbiota studies, animals may be fed maltodextrin-containing diets for several weeks, and fecal samples are collected for microbiome analysis by 16S rRNA sequencing.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of maltodextrin are characterized by its rapid digestion and absorption. Following ingestion, maltodextrin is hydrolyzed by brush-border enzymes in the small intestine into glucose, which is then absorbed via SGLT1 and GLUT2 transporters. The resulting glucose enters the portal circulation and is distributed to peripheral tissues. The pharmacokinetics of maltodextrin are essentially those of glucose, with rapid absorption, a peak in blood glucose within 30-60 minutes, and clearance by insulin-dependent and insulin-independent mechanisms.
|
| Toxicity/Toxicokinetics |
Maltodextrin is generally recognized as safe (GRAS) and has low toxicity. At concentrations of 5 mg/mL, it is non-toxic to cells in vitro. In animal studies, maltodextrin is well-tolerated at high doses. Potential adverse effects are related to its carbohydrate content, including hyperglycemia in diabetic or insulin-resistant individuals, and gastrointestinal symptoms such as bloating, gas, or diarrhea at high doses due to osmotic effects or fermentation by gut bacteria. No significant genotoxicity or carcinogenicity has been reported.
|
| References |
|
| Additional Infomation |
Maltodextrin (DE 16.5-19.5) is a widely used pharmaceutical excipient and food ingredient. It serves as a binder, filler, stabilizer, and carbohydrate source in various formulations. It is also used in cell culture media, fermentation processes, and as a stabilizer in protein formulations. In drug delivery systems, maltodextrin can be used as a matrix former for encapsulation and as a binding additive for 3D printing manufacturing. It is not a therapeutic agent and is not approved for therapeutic use as an active pharmaceutical ingredient.
|
| Molecular Formula |
(C6H10O5)N.XH2O
|
|---|---|
| Molecular Weight |
180.063385
|
| Exact Mass |
180.063
|
| CAS # |
9050-36-6
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
527.1±50.0 °C at 760 mmHg
|
| Melting Point |
240ºC (dec.)
|
| Flash Point |
286.7±26.6 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
-3.17
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5537 mL | 27.7685 mL | 55.5370 mL | |
| 5 mM | 1.1107 mL | 5.5537 mL | 11.1074 mL | |
| 10 mM | 0.5554 mL | 2.7769 mL | 5.5537 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
